Kalaris Therapeutics, Inc. (KLRS) Form 8-K — Aug 11, 2026
Kalaris Therapeutics (KLRS) reported Q2 2026 results with a net loss of $11.5 million, essentially flat versus the $11.4 million loss a year ago. R&D expense rose to $9.0 million from $8.4 million on clinical site expansion for TH103, while G&A fell to $3.4 million from $3.8 million on lower professional fees. Net loss per share improved to $(0.48) from $(0.61) on a higher share count. Cash, cash equivalents and marketable securities stood at $93.5 million as of June 30, 2026, down from $118.0 million at year-end 2025, and management expects this to fund operations into the fourth quarter of 2027.
Key figures
- Total Assets
- 99539000
- Cash Position
- 93538000
- Shares Outstanding
- 23804981
- Cash runway
- into the fourth quarter of 2027
- Cash dec 31 2025
- 117982000
- Total liabilities
- 41867000
- Ga expense q2 2025
- 3816000
- Ga expense q2 2026
- 3368000
- Phase 3 initiation
- by year-end 2027
- Rd expense q2 2025
- 8440000
- Rd expense q2 2026
- 9018000
- Stockholders equity
- 57672000
- Phase 1b 2 preliminary data
- first half of 2027
Price after filing
Close on the filing date to close N calendar days later (from $4.07). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.